{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:16:04Z","timestamp":1790712964725,"version":"4.1.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0219829","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T17:47:23Z","timestamp":1565286443000},"page":"e0219829","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Empowering therapeutic antibodies with IFN-\u03b1 for cancer immunotherapy"],"prefix":"10.1371","volume":"14","author":[{"given":"Jun","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Ladror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-7823","authenticated-orcid":true,"given":"John","family":"Harlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanushree","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medha","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Bukofzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherrie","family":"Donawho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0650-582X","authenticated-orcid":true,"given":"Tzu-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer","volume":"8","author":"Y Dong","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"G Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"e1426519","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGF-beta trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"KM Knudson","year":"2018","journal-title":"Oncoimmunology"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4161\/cbt.6.6.4088","article-title":"Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells","volume":"6","author":"A Papageorgiou","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"ref5","first-page":"483","article-title":"Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response","volume":"4","author":"G Scjiavoni","year":"2013","journal-title":"Front Immunol"},{"issue":"24","key":"ref6","first-page":"14040","article-title":"Type I interferon signaling enhance CD8+ T cells effector function and differentiation during murine gammaherpesvirus 68 infection","volume":"88","author":"RN Jennings","year":"2014"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2009-10-250555","article-title":"Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma","volume":"115","author":"C Xuan","year":"2010","journal-title":"Blood"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccr.2013.12.004","article-title":"Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses","volume":"25","author":"X Yang","year":"2014","journal-title":"Cancer Cell"},{"issue":"13","key":"ref9","article-title":"Empowering therapeutic monoclonal antibodies with IFN-alpha for cancer immunotherapy","volume":"78","author":"J Guo","year":"2018","journal-title":"Cancer Research"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-015-0397-y","article-title":"Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer","volume":"14","author":"H Zhang","year":"2015","journal-title":"Molecular Cancer"},{"key":"ref11","first-page":"328","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"W Zou","year":"2016","journal-title":"Science Translational Medicine"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type 1 interferon signaling to the efficacy of chemotherapy","volume":"20","author":"A Sistigu","year":"2014","journal-title":"Nature Medicine"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/84219","article-title":"Lymphocyte traffic control by chemokines","volume":"2","author":"B Moser","year":"2001","journal-title":"Nature Immunology"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI1422","article-title":"The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associate with certain inflammatory reactions","volume":"101","author":"S Qin","year":"1998","journal-title":"The Journal of Clinical Investigation"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3389\/fimmu.2018.02129","article-title":"Interferon-alpha up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling","volume":"9","author":"AV Bazhin","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1a, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"MZ Noman","year":"2014","journal-title":"J Exp Med"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type 1 IFN sigmals are required for antitumor CD8+ T cell responses through CD8 {alpha}+ dendritic cells","volume":"208","author":"MB Fuertes","year":"2011","journal-title":"J Exp Med"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type 1 interferon: friend or foe","volume":"207","author":"G Trinchieri","year":"2010","journal-title":"J Exp Med"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.4049\/jimmunol.179.10.6881","article-title":"Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities","volume":"179","author":"TH Huang","year":"2007","journal-title":"J Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40164-017-0081-6","article-title":"Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today\u2019s treat-to-target era","volume":"6","author":"L Zhang","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockake resistance","volume":"9","author":"Y Liang","year":"2018","journal-title":"Nature Communications"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/76932","article-title":"Selective loss of type 1 interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2","volume":"1","author":"JD Farrar","year":"2000","journal-title":"Nature Immunology"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type 1 interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"L Deng","year":"2014","journal-title":"Immunity"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T cell-inflamed tumor microenvironment","volume":"36","author":"SR Woo","year":"2015","journal-title":"Trends in Immunology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0219829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T09:20:07Z","timestamp":1610788807000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0219829"}},"subtitle":[],"editor":[{"given":"Joseph","family":"Najbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0219829","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]}}}